Evidence map›Paper›PMID 26339058›Full record

ArticleJournal of virology2015

Phenotypic Correlates of HIV-1 Macrophage Tropism.

Kathryn T Arrildt, Celia C LaBranche, Sarah B Joseph, Elena N Dukhovlinova, William D Graham, Li-Hua Ping, Gretja Schnell, Christa B Sturdevant, Laura P Kincer, Macpherson Mallewa and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Role of Monocyte/Macrophages in the Pathogenesis of NeuroHIV.Results and problems in cell differentiation · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Kathryn T ArrildtDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Celia C LaBrancheDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Sarah B JosephDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Elena N DukhovlinovaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
William D GrahamLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Li-Hua PingLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Gretja SchnellAbbVie Inc., North Chicago, Illinois, USA.
Christa B SturdevantDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Laura P KincerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Macpherson MallewaMalawi-Liverpool-Wellcome Trust Clinical Research Program, University of Malawi College of Medicine, Blantyre, Malawi Department of Paediatrics and Child Health, University of Malawi College of Medicine, Blantyre, Malawi.
Robert S HeydermanMalawi-Liverpool-Wellcome Trust Clinical Research Program, University of Malawi College of Medicine, Blantyre, Malawi.
Annelies Van RieDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Myron S CohenDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA UNC Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Serena SpudichDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.
Richard W PriceDepartment of Neurology, University of California San Francisco, San Francisco, California, USA.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Ronald SwanstromDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA UNC Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA risunc@med.unc.edu.
University of North Carolina at Chapel Hill · USDuke Medical Center · USAbbVie (United States) · USMalawi-Liverpool-Wellcome Trust Clinical Research Programme · MWUniversity of California, San Francisco · USUniversity of Liverpool · GBYale University · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
The Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0M
California NeuroAIDS Tissue NetworkU24MH100928 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACHIM, CRISTIAN L, MOORE, DAVID J · 2013 to 2023
$13.9M
NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
NNTC Data Coordinating CenterU24MH100925 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FOX, HOWARD S, SHERMAN, SETH · 2013 to 2022
$9.5M
Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Persistent CSF HIV despite successful cART: Viral Tropism, Drug Penetration andP01MH094177 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2011 to 2015
$4.5M
Compartmentalized CSF viral escape and the CNS HIV reservoirR01NS094067 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRICE, RICHARD W. · 2015 to 2020
$3.9M
Biological properties of HIV-1 V3 evolutionary variantsR37AI044667 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSTROM, RONALD I · 2005 to 2014
$3.4M
NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA16086NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI50410NIAID NIH HHS R37 AI044667NIAID NIH HHS R37 AI44667NIAID NIH HHS T32 AI007419NIAID NIH HHS T32 AI07419NIMH NIH HHS P01 MH094177NIMH NIH HHS R01 MH101024NIMH NIH HHS U24 MH100925NIMH NIH HHS U24MH100925NIMH NIH HHS U24 MH100928NIMH NIH HHS U24MH100928NIMH NIH HHS U24 MH100929NIMH NIH HHS U24MH100929NIMH NIH HHS U24 MH100930NIMH NIH HHS U24MH100930NIMH NIH HHS U24 MH100931NIMH NIH HHS U24MH100931NINDS NIH HHS R01 NS094067PHS HHS HHSN27201100016CWellcome Trust
6 · The paper itself

Abstract

unlabelledHIV-1 is typically CCR5 using (R5) and T cell tropic (T-tropic), targeting memory CD4(+) T cells throughout acute and chronic infections. However, viruses can expand into alternative cells types. Macrophage-tropic (M-tropic) HIV-1 variants have evolved to infect macrophages, which have only low levels of surface CD4. Most M-tropic variants have been isolated from the central nervous system during late-stage chronic infection. We used the HIV-1 env genes of well-defined, subject-matched M-tropic and T-tropic viruses to characterize the phenotypic features of the M-tropic Env protein. We found that, compared to T-tropic viruses, M-tropic viruses infect monocyte-derived macrophages (MDMs) on average 28-fold more efficiently, use low-density CD4 more efficiently, have increased sensitivity to soluble CD4 (sCD4), and show trends toward sensitivity to some CD4 binding site antibodies but no difference in sensitivity to antibodies targeting the CD4-bound conformation. M-tropic viruses also displayed a trend toward resistance to neutralization by monoclonal antibodies targeting the V1/V2 region of Env, suggesting subtle changes in Env protein conformation. The paired M- and T-tropic viruses did not differ in autologous serum neutralization, temperature sensitivity, entry kinetics, intrinsic infectivity, or Env protein incorporation. We also examined viruses with modestly increased CD4 usage. These variants have significant sensitivity to sCD4 and may represent evolutionary intermediates. CD4 usage is strongly correlated with infectivity of MDMs over a wide range of CD4 entry phenotypes. These data suggest that emergence of M-tropic HIV-1 includes multiple steps in which a phenotype of increased sensitivity to sCD4 and enhanced CD4 usage accompany subtle changes in Env conformation. IMPORTANCE: HIV-1 typically replicates in CD4(+) T cells. However, HIV-1 can evolve to infect macrophages, especially within the brain. Understanding how CCR5-using macrophage-tropic viruses evolve and differ from CCR5-using T cell-tropic viruses may provide insights into viral evolution and pathogenesis within the central nervous system. We characterized the HIV-1 env viral entry gene from subject-matched macrophage-tropic and T cell-tropic viruses to identify entry features of macrophage-tropic viruses. We observed several differences between T cell-tropic and macrophage-tropic Env proteins, including functional differences with host CD4 receptor engagement and possible changes in the CD4 binding site and V1/V2 region. We also identified viruses with phenotypes between that of "true" macrophage-tropic and T cell-tropic viruses, which may represent evolutionary intermediates in a multistep process to macrophage tropism.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCD4 AntigensCD4-Positive T-LymphocytesCell Line, TumorHEK293 CellsHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp160HIV Envelope Protein gp41HIV InfectionsHumansMacrophagesReceptors, CCR5Recombinant ProteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCCR5 protein, humanCD4 AntigensHIV Envelope Protein gp120HIV Envelope Protein gp160HIV Envelope Protein gp41Receptors, CCR5Recombinant Proteinsrecombinant soluble CD4

Identifiers

PMID26339058
PMCPMC4645658
OpenAlexW1797126752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.